Coherus Oncology (CHRS) Operating Margin: 2013-2025
Historic Operating Margin for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -383.14%.
- Coherus Oncology's Operating Margin rose 39108.00% to -383.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -33.36%, marking a year-over-year increase of 16919.00%. This contributed to the annual value of -41.83% for FY2024, which is 3716.00% up from last year.
- As of Q3 2025, Coherus Oncology's Operating Margin stood at -383.14%, which was up 13.63% from -443.59% recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Operating Margin ranged from a high of 17.16% in Q4 2024 and a low of -2,937.05% during Q1 2024.
- Moreover, its 3-year median value for Operating Margin was -383.14% (2025), whereas its average is -535.41%.
- Per our database at Business Quant, Coherus Oncology's Operating Margin slumped by 272,819bps in 2024 and then soared by 233,914bps in 2025.
- Quarterly analysis of 5 years shows Coherus Oncology's Operating Margin stood at -53.91% in 2021, then plummeted by 5,963bps to -113.54% in 2022, then surged by 3,825bps to -75.29% in 2023, then spiked by 9,244bps to 17.16% in 2024, then soared by 39,108bps to -383.14% in 2025.
- Its Operating Margin was -383.14% in Q3 2025, compared to -443.59% in Q2 2025 and -597.91% in Q1 2025.